Mckesson Corporation
MCK
Market Cap$90.02B
Close$
Earnings Call Q4 2025
May 8, 2025 - AI Summary
Strong Financial Performance: McKesson achieved a record full-year revenue of $359 billion, a 16% increase year-over-year (YOY). Adjusted earnings per diluted share (EPS) rose to $33.05, reflecting a growth of 20%, surpassing long-term growth targets of 12% to 14%.
Acquisitions and Strategic Growth: The company made significant moves by acquiring controlling interests in PRISM Vision and Core Ventures, which are expected to enhance their Oncology and Biopharma services. These acquisitions are projected to contribute approximately $0.60 to adjusted EPS for fiscal 2026.
Fiscal 2026 Outlook: McKesson anticipates a revenue growth of 11% to 15% for the upcoming fiscal year, with operating profit growth expected at 8% to 12%. Adjusted EPS is forecasted to range between $36.75 and $37.55, approximately 11% to 14% growth YOY.
Exclusive for Stockcircle Pro members
Sign up
$1271.90
77.9% upside
Current Fair Value
77.9% upsideUndervalued by 77.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $90.02 Billion |
|---|---|
| Enterprise Value | $91.72 Billion |
| Dividend Yield | $2.75 (0.382204555878306%) |
| Earnings per Share | $25.86 |
| Beta | 0.52 |
| Outstanding Shares | 125,200,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 27.34 |
|---|---|
| PEG | 46.11 |
| Price to Sales | 0.25 |
| Price to Book Ratio | -51.06 |
| Enterprise Value to Revenue | 0.26 |
| Enterprise Value to EBIT | 21.58 |
| Enterprise Value to Net Income | 22 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | -3.56 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Mckesson Corporation
80,000 employees
CEO: Brian Tyler McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions. McKesson partners with pharmaceutical manufacturers, p...